1
|
Njunge LW, Estania AP, Guo Y, Liu W, Yang L. Tumor progression locus 2 (TPL2) in tumor-promoting Inflammation, Tumorigenesis and Tumor Immunity. Am J Cancer Res 2020; 10:8343-8364. [PMID: 32724474 PMCID: PMC7381748 DOI: 10.7150/thno.45848] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2020] [Accepted: 06/03/2020] [Indexed: 12/15/2022] Open
Abstract
Over the years, tumor progression locus 2 (TPL2) has been identified as an essential modulator of immune responses that conveys inflammatory signals to downstream effectors, subsequently modulating the generation and function of inflammatory cells. TPL2 is also differentially expressed and activated in several cancers, where it is associated with increased inflammation, malignant transformation, angiogenesis, metastasis, poor prognosis and therapy resistance. However, the relationship between TPL2-driven inflammation, tumorigenesis and tumor immunity has not been addressed. Here, we reconcile the function of TPL2-driven inflammation to oncogenic functions such as inflammation, proliferation, apoptosis resistance, angiogenesis, metastasis, immunosuppression and immune evasion. We also address the controversies reported on TPL2 function in tumor-promoting inflammation and tumorigenesis, and highlight the potential role of the TPL2 adaptor function in regulating the mechanisms leading to pro-tumorigenic inflammation and tumor progression. We discuss the therapeutic implications and limitations of targeting TPL2 for cancer treatment. The ideas presented here provide some new insight into cancer pathophysiology that might contribute to the development of more integrative and specific anti-inflammatory and anti-cancer therapeutics.
Collapse
|
2
|
Assaying kinase activity of the TPL-2/NF-κB1 p105/ABIN-2 complex using an optimal peptide substrate. Biochem J 2018; 475:329-340. [PMID: 29229763 PMCID: PMC5763956 DOI: 10.1042/bcj20170579] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2017] [Revised: 12/08/2017] [Accepted: 12/11/2017] [Indexed: 11/17/2022]
Abstract
The MKK1/2 kinase tumour progression locus 2 (TPL-2) is critical for the production of tumour necrosis factor alpha (TNFα) in innate immune responses and a potential anti-inflammatory drug target. Several earlier pharmaceutical company screens with the isolated TPL-2 kinase domain have identified small-molecule inhibitors that specifically block TPL-2 signalling in cells, but none of these have progressed to clinical development. We have previously shown that TPL-2 catalytic activity regulates TNF production by macrophages while associated with NF-κB1 p105 and ABIN-2, independently of MKK1/2 phosphorylation via an unknown downstream substrate. In the present study, we used a positional scanning peptide library to determine the optimal substrate specificity of a complex of TPL-2, NF-κB1 p105 and ABIN-2. Using an optimal peptide substrate based on this screen and a high-throughput mass spectrometry assay to monitor kinase activity, we found that the TPL-2 complex has significantly altered sensitivities versus existing ATP-competitive TPL-2 inhibitors than the isolated TPL-2 kinase domain. These results imply that screens with the more physiologically relevant TPL-2/NF-κB1 p105/ABIN-2 complex have the potential to deliver novel TPL-2 chemical series; both ATP-competitive and allosteric inhibitors could emerge with significantly improved prospects for development as anti-inflammatory drugs.
Collapse
|
3
|
Glatthar R, Stojanovic A, Troxler T, Mattes H, Möbitz H, Beerli R, Blanz J, Gassmann E, Drückes P, Fendrich G, Gutmann S, Martiny-Baron G, Spence F, Hornfeld J, Peel JE, Sparrer H. Discovery of Imidazoquinolines as a Novel Class of Potent, Selective, and in Vivo Efficacious Cancer Osaka Thyroid (COT) Kinase Inhibitors. J Med Chem 2016; 59:7544-60. [DOI: 10.1021/acs.jmedchem.6b00598] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Affiliation(s)
- Ralf Glatthar
- Global Discovery Chemistry, ‡Analytical Sciences, §Center for Proteomic
Chemistry, ∥Preclinical Safety, and ⊥Autoimmunity
Transplantation Inflammation, Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland
| | - Aleksandar Stojanovic
- Global Discovery Chemistry, ‡Analytical Sciences, §Center for Proteomic
Chemistry, ∥Preclinical Safety, and ⊥Autoimmunity
Transplantation Inflammation, Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland
| | - Thomas Troxler
- Global Discovery Chemistry, ‡Analytical Sciences, §Center for Proteomic
Chemistry, ∥Preclinical Safety, and ⊥Autoimmunity
Transplantation Inflammation, Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland
| | - Henri Mattes
- Global Discovery Chemistry, ‡Analytical Sciences, §Center for Proteomic
Chemistry, ∥Preclinical Safety, and ⊥Autoimmunity
Transplantation Inflammation, Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland
| | - Henrik Möbitz
- Global Discovery Chemistry, ‡Analytical Sciences, §Center for Proteomic
Chemistry, ∥Preclinical Safety, and ⊥Autoimmunity
Transplantation Inflammation, Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland
| | - Rene Beerli
- Global Discovery Chemistry, ‡Analytical Sciences, §Center for Proteomic
Chemistry, ∥Preclinical Safety, and ⊥Autoimmunity
Transplantation Inflammation, Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland
| | - Joachim Blanz
- Global Discovery Chemistry, ‡Analytical Sciences, §Center for Proteomic
Chemistry, ∥Preclinical Safety, and ⊥Autoimmunity
Transplantation Inflammation, Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland
| | - Ernst Gassmann
- Global Discovery Chemistry, ‡Analytical Sciences, §Center for Proteomic
Chemistry, ∥Preclinical Safety, and ⊥Autoimmunity
Transplantation Inflammation, Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland
| | - Peter Drückes
- Global Discovery Chemistry, ‡Analytical Sciences, §Center for Proteomic
Chemistry, ∥Preclinical Safety, and ⊥Autoimmunity
Transplantation Inflammation, Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland
| | - Gabriele Fendrich
- Global Discovery Chemistry, ‡Analytical Sciences, §Center for Proteomic
Chemistry, ∥Preclinical Safety, and ⊥Autoimmunity
Transplantation Inflammation, Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland
| | - Sascha Gutmann
- Global Discovery Chemistry, ‡Analytical Sciences, §Center for Proteomic
Chemistry, ∥Preclinical Safety, and ⊥Autoimmunity
Transplantation Inflammation, Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland
| | - Georg Martiny-Baron
- Global Discovery Chemistry, ‡Analytical Sciences, §Center for Proteomic
Chemistry, ∥Preclinical Safety, and ⊥Autoimmunity
Transplantation Inflammation, Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland
| | - Fiona Spence
- Global Discovery Chemistry, ‡Analytical Sciences, §Center for Proteomic
Chemistry, ∥Preclinical Safety, and ⊥Autoimmunity
Transplantation Inflammation, Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland
| | - Jeff Hornfeld
- Global Discovery Chemistry, ‡Analytical Sciences, §Center for Proteomic
Chemistry, ∥Preclinical Safety, and ⊥Autoimmunity
Transplantation Inflammation, Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland
| | - John Edmonson Peel
- Global Discovery Chemistry, ‡Analytical Sciences, §Center for Proteomic
Chemistry, ∥Preclinical Safety, and ⊥Autoimmunity
Transplantation Inflammation, Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland
| | - Helmut Sparrer
- Global Discovery Chemistry, ‡Analytical Sciences, §Center for Proteomic
Chemistry, ∥Preclinical Safety, and ⊥Autoimmunity
Transplantation Inflammation, Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland
| |
Collapse
|
4
|
Structural simulation of adenosine phosphate via plumbagin and zoledronic acid competitively targets JNK/Erk to synergistically attenuate osteoclastogenesis in a breast cancer model. Cell Death Dis 2016; 7:e2094. [PMID: 26866274 PMCID: PMC4849151 DOI: 10.1038/cddis.2016.11] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2015] [Revised: 01/04/2016] [Accepted: 01/05/2016] [Indexed: 12/18/2022]
Abstract
The treatment of breast cancer-induced osteolysis remains a challenge in clinical settings. Here, we explored the effect and mechanism of combined treatment with zoledronic acid (ZA) and plumbagin (PL), a widely investigated component derived from Plumbago zeylanica, against breast cancer-induced osteoclastogenesis. We found that the combined treatment with PL and ZA suppressed cell viability of precursor osteoclasts and synergistically inhibited MDA-MB-231-induced osteoclast formation (combination index=0.28) with the abrogation of recombinant mouse receptor activator of nuclear factor-κB ligand (RANKL)-induced activation of NF-κB/MAPK (nuclear factor-κB/mitogen-activated protein kinase) pathways. Molecular docking suggested a putative binding area within c-Jun N-terminal kinase/extracellular signal-regulated kinase (JNK/Erk) protease active sites through the structural mimicking of adenosine phosphate (ANP) by the spatial combination of PL with ZA. A homogeneous time-resolved fluorescence assay further illustrated the direct competitiveness of the dual drugs against ANP docking to phosphorylated JNK/Erk, contributing to the inhibited downstream expression of c-Jun/c-Fos/NFATc-1 (nuclear factor of activated T cells, cytoplasmic, calcineurin-dependent 1). Then, in vivo testing demonstrated that the combined administration of PL and ZA attenuated breast cancer growth in the bone microenvironment. Additionally, these molecules prevented the destruction of proximal tibia, with significant reduction of tartrate-resistant acid phosphatase (TRAcP)-positive osteoclast cells and potentiation of apoptotic cancer cells, to a greater extent when combined than when the drugs were applied independently. Altogether, the combination treatment with PL and ZA could significantly and synergistically suppress osteoclastogenesis and inhibit tumorigenesis both in vitro and in vivo by simulating the spatial structure of ANP to inhibit competitively phosphorylation of c-Jun N-terminal kinase/extracellular signal-regulated kinase (JNK/Erk).
Collapse
|
5
|
Gutmann S, Hinniger A, Fendrich G, Drückes P, Antz S, Mattes H, Möbitz H, Ofner S, Schmiedeberg N, Stojanovic A, Rieffel S, Strauss A, Troxler T, Glatthar R, Sparrer H. The Crystal Structure of Cancer Osaka Thyroid Kinase Reveals an Unexpected Kinase Domain Fold. J Biol Chem 2015; 290:15210-8. [PMID: 25918157 DOI: 10.1074/jbc.m115.648097] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2015] [Indexed: 12/31/2022] Open
Abstract
Macrophages are important cellular effectors in innate immune responses and play a major role in autoimmune diseases such as rheumatoid arthritis. Cancer Osaka thyroid (COT) kinase, also known as mitogen-activated protein kinase kinase kinase 8 (MAP3K8) and tumor progression locus 2 (Tpl-2), is a serine-threonine (ST) kinase and is a key regulator in the production of pro-inflammatory cytokines in macrophages. Due to its pivotal role in immune biology, COT kinase has been identified as an attractive target for pharmaceutical research that is directed at the discovery of orally available, selective, and potent inhibitors for the treatment of autoimmune disorders and cancer. The production of monomeric, recombinant COT kinase has proven to be very difficult, and issues with solubility and stability of the enzyme have hampered the discovery and optimization of potent and selective inhibitors. We developed a protocol for the production of recombinant human COT kinase that yields pure and highly active enzyme in sufficient yields for biochemical and structural studies. The quality of the enzyme allowed us to establish a robust in vitro phosphorylation assay for the efficient biochemical characterization of COT kinase inhibitors and to determine the x-ray co-crystal structures of the COT kinase domain in complex with two ATP-binding site inhibitors. The structures presented in this study reveal two distinct ligand binding modes and a unique kinase domain architecture that has not been observed previously. The structurally versatile active site significantly impacts the design of potent, low molecular weight COT kinase inhibitors.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | - Helmut Sparrer
- Autoimmunity Transplantation Inflammation, Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4002 Basel, Switzerland
| |
Collapse
|
6
|
IκB kinase-induced interaction of TPL-2 kinase with 14-3-3 is essential for Toll-like receptor activation of ERK-1 and -2 MAP kinases. Proc Natl Acad Sci U S A 2014; 111:E2394-403. [PMID: 24912162 DOI: 10.1073/pnas.1320440111] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
The MEK-1/2 kinase TPL-2 is critical for Toll-like receptor activation of the ERK-1/2 MAP kinase pathway during inflammatory responses, but it can transform cells following C-terminal truncation. IκB kinase (IKK) complex phosphorylation of the TPL-2 C terminus regulates full-length TPL-2 activation of ERK-1/2 by a mechanism that has remained obscure. Here, we show that TPL-2 Ser-400 phosphorylation by IKK and TPL-2 Ser-443 autophosphorylation cooperated to trigger TPL-2 association with 14-3-3. Recruitment of 14-3-3 to the phosphorylated C terminus stimulated TPL-2 MEK-1 kinase activity, which was essential for TPL-2 activation of ERK-1/2. The binding of 14-3-3 to TPL-2 was also indispensible for lipopolysaccharide-induced production of tumor necrosis factor by macrophages, which is regulated by TPL-2 independently of ERK-1/2 activation. Our data identify a key step in the activation of TPL-2 signaling and provide a mechanistic insight into how C-terminal deletion triggers the oncogenic potential of TPL-2 by rendering its kinase activity independent of 14-3-3 binding.
Collapse
|
7
|
Ebola virus VP35 induces high-level production of recombinant TPL-2-ABIN-2-NF-κB1 p105 complex in co-transfected HEK-293 cells. Biochem J 2013; 452:359-65. [PMID: 23557442 PMCID: PMC3727213 DOI: 10.1042/bj20121873] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Activation of PKR (double-stranded-RNA-dependent protein kinase) by DNA plasmids decreases translation, and limits the amount of recombinant protein produced by transiently transfected HEK (human embryonic kidney)-293 cells. Co-expression with Ebola virus VP35 (virus protein 35), which blocked plasmid activation of PKR, substantially increased production of recombinant TPL-2 (tumour progression locus 2)–ABIN-2 [A20-binding inhibitor of NF-κB (nuclear factor κB) 2]–NF-κB1 p105 complex. VP35 also increased expression of other co-transfected proteins, suggesting that VP35 could be employed generally to boost recombinant protein production by HEK-293 cells.
Collapse
|
8
|
Abstract
BACKGROUND Homogeneous time-resolved fluorescence (HTRF) is a fluorescence resonance energy transfer-based technology used to measure bimolecular interactions. It has been applied successfully to kinase assays and has become an important tool in kinase drug discovery. OBJECTIVE This article reviews the current status of HTRF technology in biochemical and cellular kinase assays. METHODS Recent literature and meeting reports on HTRF kinase assays are reviewed, and their principles, advantages and drawbacks, current status and the potential applications in kinase drug discovery are discussed. RESULTS/CONCLUSION HTRF kinase assays are homogeneous, robust, sensitive, easy to miniaturize and high-throughput. This assay format is versatile, as both peptide and protein substrates can be used, and high ATP concentrations are tolerated, which enables the assay to be performed under conditions mimicking the physiological environment. HTRF kinase assays have been applied to both high-throughput screening and compound mechanistic studies. Besides protein kinases, the technology has now been expanded into the lipid kinase family. Furthermore, the utility of HTRF technology in cellular assays is emerging. HTRF kinase assays are a great addition to the toolbox for kinase drug discovery.
Collapse
Affiliation(s)
- Yong Jia
- Group Leader Genomics Institute of the Novartis Research Foundation, Department of Kinase Biology, 10675 John J Hopkins Dr, San Diego, CA 92121, USA +858 812 1728 ; +858 812 1918 ;
| |
Collapse
|
9
|
IκB kinase 2 regulates TPL-2 activation of extracellular signal-regulated kinases 1 and 2 by direct phosphorylation of TPL-2 serine 400. Mol Cell Biol 2012; 32:4684-90. [PMID: 22988300 DOI: 10.1128/mcb.01065-12] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023] Open
Abstract
Tumor progression locus 2 (TPL-2) functions as a MEK-1/2 kinase, which is essential for Toll-like receptor 4 (TLR4) activation of extracellular signal-regulated kinase 1 and 2 (ERK-1/2) mitogen-activated protein (MAP) kinases in lipopolysaccharide (LPS)-stimulated macrophages and for inducing the production of the proinflammatory cytokines tumor necrosis factor and interleukin-1β. In unstimulated cells, association of TPL-2 with NF-κB1 p105 prevents TPL-2 phosphorylation of MEK-1/2. LPS stimulation of TPL-2 MEK-1/2 kinase activity requires TPL-2 release from p105. This is triggered by IκB kinase 2 (IKK-2) phosphorylation of the p105 PEST region, which promotes p105 ubiquitination and degradation by the proteasome. LPS activation of ERK-1/2 additionally requires transphosphorylation of TPL-2 on serine 400 in its C terminus, which controls TPL-2 signaling to ERK-1/2 independently of p105. However, the identity of the protein kinase responsible for TPL-2 serine 400 phosphorylation remained unknown. In the present study, we show that TPL-2 serine 400 phosphorylation is mediated by IKK2. The IKK complex therefore regulates two of the key regulatory steps required for TPL-2 activation of ERK-1/2, underlining the close linkage of ERK-1/2 MAP kinase activation to upregulation of NF-κB-dependent transcription.
Collapse
|
10
|
Gantke T, Sriskantharajah S, Sadowski M, Ley SC. IκB kinase regulation of the TPL-2/ERK MAPK pathway. Immunol Rev 2012; 246:168-82. [DOI: 10.1111/j.1600-065x.2012.01104.x] [Citation(s) in RCA: 105] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
11
|
Regulation and function of TPL-2, an IκB kinase-regulated MAP kinase kinase kinase. Cell Res 2010; 21:131-45. [PMID: 21135874 DOI: 10.1038/cr.2010.173] [Citation(s) in RCA: 103] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
The IκB kinase (IKK) complex plays a well-documented role in innate and adaptive immunity. This function has been widely attributed to its role as the central activator of the NF-κB family of transcription factors. However, another important consequence of IKK activation is the regulation of TPL-2, a MEK kinase that is required for activation of ERK-1/2 MAP kinases in myeloid cells following Toll-like receptor and TNF receptor stimulation. In unstimulated cells, TPL-2 is stoichiometrically complexed with the NF-κB inhibitory protein NF-κB1 p105, which blocks TPL-2 access to its substrate MEK, and the ubiquitin-binding protein ABIN-2 (A20-binding inhibitor of NF-κB 2), both of which are required to maintain TPL-2 protein stability. Following agonist stimulation, the IKK complex phosphorylates p105, triggering its K48-linked ubiquitination and degradation by the proteasome. This releases TPL-2 from p105-mediated inhibition, facilitating activation of MEK, in addition to modulating NF-κB activation by liberating associated Rel subunits for translocation into the nucleus. IKK-induced proteolysis of p105, therefore, can directly regulate both NF-κB and ERK MAP kinase activation via NF-κB1 p105. TPL-2 is critical for production of the proinflammatory cytokine TNF during inflammatory responses. Consequently, there has been considerable interest in the pharmaceutical industry to develop selective TPL-2 inhibitors as drugs for the treatment of TNF-dependent inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease. This review summarizes our current understanding of the regulation of TPL-2 signaling function, and also the complex positive and negative roles of TPL-2 in immune and inflammatory responses.
Collapse
|
12
|
George D, Friedman M, Allen H, Argiriadi M, Barberis C, Bischoff A, Clabbers A, Cusack K, Dixon R, Fix-Stenzel S, Gordon T, Janssen B, Jia Y, Moskey M, Quinn C, Salmeron JA, Wishart N, Woller K, Yu Z. Discovery of thieno[2,3-c]pyridines as potent COT inhibitors. Bioorg Med Chem Lett 2008; 18:4952-5. [PMID: 18755587 DOI: 10.1016/j.bmcl.2008.08.037] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2008] [Revised: 08/11/2008] [Accepted: 08/11/2008] [Indexed: 12/23/2022]
Abstract
Evaluation of hit chemotypes from high throughput screening identified a novel series of 2,4-disubstituted thieno[2,3-c]pyridines as COT kinase inhibitors. Structural modifications exploring SAR at the 2- and 4-positions resulting in inhibitors with improved enzyme potency and cellular activity are disclosed.
Collapse
Affiliation(s)
- Dawn George
- Abbott Bioresearch Center, 381 Plantation Street, Worcester, MA 01605, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Jia Y, Quinn CM, Talanian RV. Designingin vitroassays for drug discovery: a study with the human MAP3 kinase COT. Expert Opin Drug Discov 2007; 2:909-15. [DOI: 10.1517/17460441.2.7.909] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
|
14
|
Jia Y, Quinn CM, Clabbers A, Talanian R, Xu Y, Wishart N, Allen H. Comparative analysis of various in vitro COT kinase assay formats and their applications in inhibitor identification and characterization. Anal Biochem 2005; 350:268-76. [PMID: 16356459 DOI: 10.1016/j.ab.2005.11.010] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2005] [Revised: 11/02/2005] [Accepted: 11/03/2005] [Indexed: 10/25/2022]
Abstract
Cancer osaka thyroid (COT) is a member of the mitogen-activated protein kinase kinase kinase family of enzymes and plays a pivotal role in tumor necrosis factor-alpha production in macrophages. Consequently, COT is considered to be a promising target for antiinflammatory drug discovery. We describe here the development of in vitro COT assays in several formats and the advantages and disadvantages of each. A cascade assay requires very small amounts of enzyme and can provide a useful tool for high-throughput screening, but it is not desirable for compound mechanistic studies due to complicated kinetics. Direct assays are superior to cascade assays and are suitable for both compound screening and mechanistic studies. Among the direct assays, the homogeneous time-resolved fluorescence (HTRF) format is preferred over the radiometric format due to the robustness, throughput, and ease of use of the HTRF format. When the physiological protein substrate MEK1 (MAP/Erk kinase 1) was used to determine inhibitor potencies, false positives were observed due to compound interference by binding to MEK1. Using a MEK1 peptide substrate, these false positives were eliminated. In addition, we describe a simple method to study the ATP competitiveness of compounds. The knowledge gained through our studies with COT, and the methods described for our assays and compound mechanistic studies, can be readily applied to other kinase targets.
Collapse
Affiliation(s)
- Yong Jia
- Department of Molecular Pharmacology, Abbott Bioresearch Center, Worcester, MA 01605, USA.
| | | | | | | | | | | | | |
Collapse
|